{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:38:16Z","timestamp":1794008296443,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10549-021-06246-z","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T13:03:25Z","timestamp":1620479005000},"page":"225-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Leptomeningeal Metastasis in ER\u2009+\u2009HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period"],"prefix":"10.1007","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-895X","authenticated-orcid":false,"given":"Junichiro","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8956-5427","authenticated-orcid":false,"given":"Koichi","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8043-8608","authenticated-orcid":false,"given":"Shogo","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2424-2314","authenticated-orcid":false,"given":"Shoichi","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4170-7304","authenticated-orcid":false,"given":"Nakamasa","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-5707","authenticated-orcid":false,"given":"Yoko","family":"Nakasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"key":"6246_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11060-016-2075-3","volume":"127","author":"R Rostami","year":"2016","unstructured":"Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B (2016) Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol 127:407\u2013414. https:\/\/doi.org\/10.1007\/s11060-016-2075-3","journal-title":"J Neurooncol"},{"key":"6246_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-017-4107-x","volume":"162","author":"S Matsuo","year":"2017","unstructured":"Matsuo S, Watanabe J, Mitsuya K, Hayashi N, Nakasu Y, Hayashi M (2017) Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. Breast Cancer Res Treat 162:169\u2013179. https:\/\/doi.org\/10.1007\/s10549-017-4107-x","journal-title":"Breast Cancer Res Treat"},{"key":"6246_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","volume":"121","author":"A Darlix","year":"2019","unstructured":"Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Delaloge S, Campone M, Augereau P, Ferrero JM, Levy C, Fumet J-D, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Chevrot M, Pasquier D, Bachelot T (2019) Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer 121:991\u20131000. https:\/\/doi.org\/10.1038\/s41416-019-0619-y","journal-title":"Br J Cancer"},{"key":"6246_CR4","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/jco.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O\u2019Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP (2020) Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J ClinOncol 38:2610\u20132619. https:\/\/doi.org\/10.1200\/jco.20.00775","journal-title":"J ClinOncol"},{"key":"6246_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/jco.18.01511","volume":"37","author":"RA Freedman","year":"2019","unstructured":"Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O\u2019Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU (2019) TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J ClinOncol 37:1081\u20131089. https:\/\/doi.org\/10.1200\/jco.18.01511","journal-title":"J ClinOncol"},{"key":"6246_CR6","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/jco.20.00147","volume":"38","author":"C Saura","year":"2020","unstructured":"Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A (2020) Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial. J ClinOncol 38:3138\u20133149. https:\/\/doi.org\/10.1200\/jco.20.00147","journal-title":"J ClinOncol"},{"key":"6246_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, Hatschek T, Kelly CM, Pe\u00f1a-Murillo C, Yilmaz M, Donica M, Ellis P (2020) Trastuzumabemtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol 31:1350\u20131358. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.020","journal-title":"Ann Oncol"},{"key":"6246_CR8","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.annonc.2020.03.239","volume":"31","author":"G Jerusalem","year":"2020","unstructured":"Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Chen S, Cathcart J, Lee C, Perrin C (2020) 138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumabderuxtecan: DESTINY-Breast01 subgroup analyses. Ann Oncol 31:S63\u2013S64. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.239","journal-title":"Ann Oncol"},{"key":"6246_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.critrevonc.2019.01.020","volume":"135","author":"MA Franzoi","year":"2019","unstructured":"Franzoi MA, Hortobagyi GN (2019) Leptomeningealcarcinomatosis in patients with breast cancer. Crit Rev OncolHematol 135:85\u201394. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.01.020","journal-title":"Crit Rev OncolHematol"},{"key":"6246_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-013-1175-6","volume":"114","author":"S Yust-Katz","year":"2013","unstructured":"Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, Penas-Prado M, Groves MD (2013) Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol 114:229\u2013235. https:\/\/doi.org\/10.1007\/s11060-013-1175-6","journal-title":"J Neurooncol"},{"key":"6246_CR11","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/annonc\/mdh432","volume":"15","author":"K Slimane","year":"2004","unstructured":"Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, Massard C, Spielmann M (2004) Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 15:1640\u20131644. https:\/\/doi.org\/10.1093\/annonc\/mdh432","journal-title":"Ann Oncol"},{"key":"6246_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/01.pas.0000213306.05811.b9","volume":"30","author":"DG Hicks","year":"2006","unstructured":"Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G, Weil RJ (2006) Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5\/6, and overexpress HER2 or EGFR. Am J SurgPathol 30:1097\u20131104. https:\/\/doi.org\/10.1097\/01.pas.0000213306.05811.b9","journal-title":"Am J SurgPathol"},{"key":"6246_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10549-017-4478-z","volume":"166","author":"J Watanabe","year":"2017","unstructured":"Watanabe J, Hayashi T, Tadokoro Y, Nishimura S, Takahashi K (2017) Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. Breast Cancer Res Treat 166:911\u2013917. https:\/\/doi.org\/10.1007\/s10549-017-4478-z","journal-title":"Breast Cancer Res Treat"},{"key":"6246_CR14","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple negative breast cancer. N Engl J Med 363:1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389","journal-title":"N Engl J Med"},{"key":"6246_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133:571\u2013573. https:\/\/doi.org\/10.1016\/S0140-6736(00)49915-0","journal-title":"Lancet"},{"key":"6246_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/1097-0142(19830101)51:1<154::AID-CNCR2820510130>3.0.CO;2-K","volume":"51","author":"CP Kokkoris","year":"1983","unstructured":"Kokkoris CP (1983) Leptomeningealcarcinomatosis: how does cancer reach the pia-arachnoid? Cancer 51:154\u2013160. https:\/\/doi.org\/10.1002\/1097-0142(19830101)51:1%3c154::AID-CNCR2820510130%3e3.0.CO;2-K","journal-title":"Cancer"},{"key":"6246_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ijrobp.2015.11.022","volume":"94","author":"MD Johnson","year":"2016","unstructured":"Johnson MD, Avkshtol V, Baschnagel AM, Meyer K, Ye H, Grills IS, Chen PY, Maitz A, Olson RE, Pieper DR, Krauss DJ (2016) Surgical resection of brain metastases and the risk of leptomeningeal recurrence in patients treated with stereotactic radiosurgery. Int J Radiation OncolBiolPhys 94:537\u2013543. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.11.022","journal-title":"Int J Radiation OncolBiolPhys"},{"key":"6246_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","volume":"168","author":"A Boire","year":"2017","unstructured":"Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, Massagu\u00e9 J (2017) complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168:1101\u20131113. https:\/\/doi.org\/10.1016\/j.cell.2017.02.025","journal-title":"Cell"},{"key":"6246_CR19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.celrep.2014.02.014","volume":"6","author":"MS Cho","year":"2014","unstructured":"Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J et al (2014) Autocrine effects of tumor-derived complement. Cell Rep 6:1085\u20131095. https:\/\/doi.org\/10.1016\/j.celrep.2014.02.014","journal-title":"Cell Rep"},{"key":"6246_CR20","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/cancers13061209","volume":"13","author":"RM O'Brien","year":"2021","unstructured":"O\u2019Brien RM, Cannon A, Reynolds JV, Lysaght J, Lynam-Lennon N (2021) Complement in tumourigenesis and the response to cancer therapy. Cancers (Basel) 13:1209. https:\/\/doi.org\/10.3390\/cancers13061209","journal-title":"Cancers (Basel)"},{"key":"6246_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10585-020-10019-1","volume":"37","author":"DA Brown","year":"2020","unstructured":"Brown DA, Lu VM, Himes BT, Burns TC, Qui\u00f1ones-Hinojosa A, Chaichana KL, Parney IF (2020) Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis. ClinExp Metastasis 37:341\u2013352. https:\/\/doi.org\/10.1007\/s10585-020-10019-1","journal-title":"ClinExp Metastasis"},{"key":"6246_CR22","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2214\/AJR.13.11156","volume":"202","author":"H He","year":"2014","unstructured":"He H, Gonzalez A, Robinson E, Yang WT (2014) Distant metastatic disease manifestations in infiltrating lobular carcinoma of the breast. AJR Am J Roentgenol 202:1140\u20131148. https:\/\/doi.org\/10.2214\/AJR.13.11156","journal-title":"AJR Am J Roentgenol"},{"key":"6246_CR23","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","volume":"19","author":"R Largillier","year":"2008","unstructured":"Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E (2008) Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 19:2012\u20132019. https:\/\/doi.org\/10.1093\/annonc\/mdn424","journal-title":"Ann Oncol"},{"key":"6246_CR24","doi-asserted-by":"publisher","first-page":"9254","DOI":"10.1038\/s41598-017-10166-8","volume":"23","author":"MT Chen","year":"2017","unstructured":"Chen MT, Sun HF, Zhao Y, Fu WY, Yang LP, Gao SP, Li LD, Jiang HL, Jin W (2017) Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. Sci Rep 23:9254. https:\/\/doi.org\/10.1038\/s41598-017-10166-8","journal-title":"Sci Rep"},{"key":"6246_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","volume":"12","author":"R Wang","year":"2019","unstructured":"Wang R, Zhu Y, Liu X, Liao X, He J, Niu L (2019) The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 12:1091. https:\/\/doi.org\/10.1186\/s12885-019-6311-z","journal-title":"BMC Cancer"},{"key":"6246_CR26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaoncol.2017.0001","volume":"3","author":"AM Martin","year":"2017","unstructured":"Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA (2017) Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol 3:1069\u20131077. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0001","journal-title":"JAMA Oncol"},{"key":"6246_CR27","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortes J, Curigliano G, Dieras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP (2018) 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 29:1634\u20131657. https:\/\/doi.org\/10.1093\/annonc\/mdy192","journal-title":"Ann Oncol"},{"key":"6246_CR28","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","volume":"74","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM (2010) Leptomeningeal metastases in the MRI era. Neurology 74:1449\u20131454. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1a69","journal-title":"Neurology"},{"key":"6246_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10072-014-1881-7","volume":"36","author":"MG Passarin","year":"2015","unstructured":"Passarin MG, Sava T, Furlanetto J, Molino A, Nortilli R, Musso AM, Zaninelli M, Franceschi T, Orrico D, Marangoni S, Dealis C, Graiff C, Filippo R, Grisanti S, Simoncini E, Vassalli L, Berruti A, Pedersini R (2015) Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. NeurolSci 36:117\u2013123. https:\/\/doi.org\/10.1007\/s10072-014-1881-7","journal-title":"NeurolSci"},{"key":"6246_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx221","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rud\u00e0 R, Preusser M (2017) EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx221","journal-title":"Ann Oncol"},{"key":"6246_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10072-014-1881-7","volume":"36","author":"MG Passarin","year":"2015","unstructured":"Passarin MG, Sava T, Furlanetto J, Molino A, Nortilli R, Musso AM, Zaninelli M, Franceschi T, Orrico D, Marangoni S, Dealis C, Graiff C, Filippo R, Grisanti S, Simoncini E, Vassalli L, Berruti A, Pedersini R (2015) Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. NeuroSci 36:117\u2013123. https:\/\/doi.org\/10.1007\/s10072-014-1881-7","journal-title":"NeuroSci"},{"key":"6246_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","volume":"17","author":"A Morikawa","year":"2017","unstructured":"Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, Seidman AD (2017) Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer 17:23\u201328. https:\/\/doi.org\/10.1016\/j.clbc.2016.07.002","journal-title":"Clin Breast Cancer"},{"key":"6246_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11060-017-2452-6","volume":"133","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun E, Rud\u00e0 R, Devos P, Hoang-Xuan K, Brandsma D, P\u00e9rez Segura P, Soffietti R, Weller M (2017) Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. J Neurooncol 133:419\u2013427. https:\/\/doi.org\/10.1007\/s11060-017-2452-6","journal-title":"J Neurooncol"},{"key":"6246_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","volume":"5","author":"PA Northcott","year":"2019","unstructured":"Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, Rutkowski S, Ellison DW, Malkin D, Taylor MD, Gajjar A, Pfister SM (2019) Medulloblastoma. Nat Rev Dis Primers 5:11. https:\/\/doi.org\/10.1038\/s41572-019-0063-6","journal-title":"Nat Rev Dis Primers"},{"key":"6246_CR35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12885-020-06984-1","volume":"20","author":"M Devecka","year":"2020","unstructured":"Devecka M, Duma MN, Wilkens JJ, Kampfer S, Borm KJ, M\u00fcnch S, Straube C, Combs SE (2020) Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting. BMC Cancer 20:501. https:\/\/doi.org\/10.1186\/s12885-020-06984-1","journal-title":"BMC Cancer"},{"key":"6246_CR36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/neuonc\/noz201","volume":"22","author":"E Le Rhun","year":"2020","unstructured":"Le Rhun E, Wallet J, Mailliez A, Le Deley MC, Rodrigues I, Boulanger T, Lorgis V, Barri\u00e8re J, Robin YM, Weller M, Bonneterre J (2020) Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. NeuroOncol 22:524\u2013538. https:\/\/doi.org\/10.1093\/neuonc\/noz201","journal-title":"NeuroOncol"},{"key":"6246_CR37","doi-asserted-by":"publisher","first-page":"102046","DOI":"10.1016\/j.ctrv.2020.102046","volume":"88","author":"F Zagouri","year":"2020","unstructured":"Zagouri F, Zoumpourlis P, Le Rhun E, Bartsch R, Zografos E, Apostolidou K, Dimopoulos MA, Preusser M (2020) Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: a metanalysis with meta-regression. Cancer Treat Rev 88:102046. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102046","journal-title":"Cancer Treat Rev"},{"key":"6246_CR38","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1158\/1078-0432.Ccr-06-2854","volume":"13","author":"JF Deeken","year":"2007","unstructured":"Deeken JF, L\u00f6scher W (2007) The blood-brain barrier and cancer: transporters, treatment, and trojan horses. Clin Cancer Res 13:1663\u20131674. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-2854","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06246-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06246-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06246-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T07:28:25Z","timestamp":1635146905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06246-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["6246"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06246-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JW reports having received personal fees from AstraZeneca, Chugai Pharmaceuticals, Daiichi-Sankyo, Eisai Co., Ltd., Eli-Lilly, Novartis Pharma, Pfizer, and Taiho Pharmaceuticals outside the submitted work. HH reports having received; personal fees from AstraZeneca, Brain Lab, Chugai Pharmaceuticals, Daiichi-Sankyo, Eli-Lilly, Novartis Pharma and Pfizer; grants from Japan Agency for Medical Research and Development, The National Cancer Center Research and Development fund, Health, Labor and Welfare Science Research Grant; outside the submitted work. The other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}